Tweet

Canine Atopic Dermatitis Treatment Receives Funding

Author: Imulan
Posted: Wednesday 3rd August, 2011. 17:39:53

Imulan BioTherapeutics, LLC (IMULAN) announced they have received a grant from the American Kennel Club entitled, “Placebo-controlled trial of T-cell receptor (TCR) peptide treatment in dogs with non-responsive atopic dermatitis”. IMULAN’s T-Cell Receptor (TCR) peptide vaccine has previously shown significant benefits in blinded, placebo controlled studies in dogs with atopic dermatitis. IMULAN is continuing work to obtain regulatory approval as a treatment for dogs with atopic dermatitis.

Daniel Gingerich DVM, IMULAN’s Chief Scientific Officer stated, “We are pleased to receive a grant from the American Kennel Club to continue our work in canine atopy. The therapeutic vaccine appears to be a very promising approach in dogs with moderate to severe atopy. The vaccine works by modulating over-responsive immune cells, thereby approaching the skin condition at the underlying immunological source of the problem.”

Canine atopic dermatitis is a prevalent condition in dogs affecting up to 5% of the dog population. Atopic dermatitis in dogs is comparable to human atopic dermatitis and eczema, including alterations in immune profiles and sensitivity to allergens. Clinical signs of atopic dermatitis include pruritus (itching) and an increase in topical skin infections such as staphylococcal pyoderma. The T-cell receptor peptides are a new class of immunobiologic that modulates T-helper cell function and increases cell mediated immunity. IMULAN’s TCR peptides have also been evaluated in models of retroviral infection, fungal infection, feline stomatitis, and canine dilated cardiomyopathy.

This article has been viewed 546 times.

 

Comments about this article